

Technology/ Title	DBPR22998/ A QPCTL (IsoQC) Inhibitor Targeting CD47-SIRP α Axis for Cancer Immunotherapy	
Subtitle		
Technology Type	<input type="checkbox"/> Biotechnology <input checked="" type="checkbox"/> Pharmaceutical	<input type="checkbox"/> Device/Diagnostics
Contact Person	Name: Cindy Hsieh	Title: Manager
	Telephone(work): +886-37246166-33209	Mobile:
	Email: wenchuan@nhri.edu.tw	
Link		
Technology Description	<p>Introduction:</p> <p>CD47-SIRPα "Do-not-eat- me" signaling axis is myeloid-specific innate immune checkpoint. Cancer cells express CD47 on the cell surface enable them to evade detection by the innate immune system and thus avoid destruction by macrophages.</p> <p><u>Key Features</u></p> <ul style="list-style-type: none"> • An orally bioavailable small molecule isoQC (QPCTL) inhibitor modulating CD47-SIRPα "Do not eat me" cancer immune checkpoint activities • Target post translational modification process of CD47 protein synthesis • Opportunity for combination with anti-tumor antibody therapeutics, chemotherapy, radiation and immune checkpoint inhibitors (ICIs) <p><u>Pharmaceutical Development</u></p> <ul style="list-style-type: none"> • Crystalline form identified; physicochemical properties/pre-formulation/formulation evaluation completed • Preclinical kilogram-scale production of the active pharmaceutical ingredient (API) available. • Non-GLP 14-day repeated-dose toxicity studies in rats completed, providing valuable insights into the safety profile. <p><u>Market Positioning</u></p> <p>As opposed to anti-CD47 antibody approaches in clinical development, our small molecule isoQC (QPCTL) inhibitor DBPR22998 is a best-in-class and innovative therapeutic approach for boosting the efficiency of cancer immunotherapy while avoiding anti-CD47 antibody-induced anemia and thrombocytopenia</p>	
Intellectual Property	US/PCT patents	

Key Publications	NA
Business Opportunity	Technology transfer; Co-development

DBPR22998 : A Potent QPCTL (IsoQC) Inhibitor Targeting CD47-SIRP α Signal

